Home › Companies › JANX

Janux Therapeutics, Inc.

JANX Lead: Phase 1 2 Biotech Distilled articles ↓

Oncology Protein

Most recent annual filing: 2026-02-26

Pipeline (3 active programs)

JANX007

Protein Target: PSMA, CD3

Metastatic Castration-Resistant Prostate Cancer Phase 1

JANX008

Protein Target: EGFR, CD3

Undisclosed indication Phase 1

JANX011

Protein Target: CD19, CD3

Undisclosed indication Phase 1 subcutaneous

Technology platforms

TRACTr

Tumor Activated T Cell Engager platform — bispecific molecules with tumor antigen-binding domain and CD3 T cell binding domain, with tumor-protease-cleavable peptide masks and albumin-binding domain for extended half-life; focus on solid tumors in oncology

Targets: CD3

TRACIr

Tumor Activated Immunomodulator platform — bispecific molecules with tumor antigen-binding domain and costimulatory CD28 binding domain; designed to enhance T cell activation and durability; focus on solid tumors in oncology

Targets: CD28

ARM

Adaptive Immune Response Modulator platform — redesigned bispecific T cell engagers targeting B cells via CD19 for rapid, deep and durable B-cell depletion with memory B-cell reset; off-the-shelf, subcutaneous, re-dosable format; focus on autoimmune diseases and oncology

Targets: CD19, CD3

Biotech Distilled coverage (2)

2026-05-09 UPDATE: Janux Therapeutics (JANX) - The BMS Milestone Hits, the Catalyst Slips 🔒 Paid
2026-04-29 Janux Pharmaceuticals (JANX) - Scientific Deep Dive for JANX007 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.